Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: April 2013

9 - Enabling Drug Discovery Technologies for Regenerative Pharmacology

from Section II - Enabling Technologies for Regenerative Pharmacology

References

1. LesneyM.Patents and potions: entering pharmaceutical industry.” The Pharmaceutical Century: Ten Decades of drug Discovery Supplement to the American Chemical Society; 2000, p. 18–31. American Chemical Society Publications, Washington DC.
2. DrewsJ.Drug discovery: a historical perspective.” Science. 2000; 287, 1960–1964.
3. DrewsJ. “In quest of tomorrow's medicines.” New York: Springer 1998.
4. MayrLM, FuerstP. “The future of high throughput screening.” J Biomol Screen. 2008; 13, 443–448.
5. GarnierJ.Rebuilding the R&D engine in big pharma.” Harvard Bus Rev. 2008; 86, 68–76.
6. MacarronR, BanksMN, Bojanic, D, Burns, DJ, CirovicDA, GaryantesT, GreenDVS, HertzbergRP, JanzenWP, PaslayJW, SchopferU, SittampalamGS. “Impact of high throughput screening in biomedical research.” Nat Rev Drug Disc. 2011; 10, 188–195.
7. AnderssonK-E, ChristGJ. Regenerative pharmacology: the future is now.” Mol Interv. 2007; 7, 79–86.
8. NirmalanandhanVS, SittampalamGS.Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges.” J Biomol Screen. 2009; 14, 755–768.
9. Furth, ME, ChristGJ. “Regenerative pharmacology for diabetes mellitus.” Mol Interv. 2009; 9, 171–174.
10.“2020: A New Vision – A Future for Regenerative Medicine.” Washington, DC: US Department of Health and Human Services. http://www.hhs.gov/reference/newfuture.shtml.
11. NelsonTJ, BehfarA, TerzicA.Stem cells: biologics for regeneration.” Clin Pharm Ther. 2008; 84, 620–623.
12. EggertUS, Superti-FurgaG. “Drugs in action.” Nat Chem Biol.2008; 4(1), 7–11.
13. Royal Society of Chemistry. Advances in Chemical Sciences. “Chemical Biology – A Vital Partnership for Progress.” 2006. http://www.rsc.org/ScienceAndTechnology/Policy/Bulletins/Issue3/Chemicalbiology.asp.
14. DrewsJ. “Genomic sciences and the medicine of tomorrow.”Nat Biotechnol. 1996; 14, 1516–1518.
15. DuFortCC, PaszekMJ, WeaverVM. “Balancing forces: architectural control of mechanotransduction.” Nat Rev Mol Cell Biol. 2011; 12, 308–319.
16. CrooksSL, CharelsLJ. “Overview of combinatorial chemistry.” Curr Protoc Pharmacol. 2000; 9(3), 1–16.
17. MaltaisR, TremblayMR, CiobanuLC, PoirierD. “Steroids and combinatorial chemistry.” J Comb Chem. 2004; 6(4), 443–456.
18. DreckerS. “Necessity is the mother of invention.” BioTEK Technical Bulletin. 2004. GIT Labor-Fachzeitschrift 12/2004, S. 1120-1121, GIT VERLAG GmbH & Co. KG, Darmstadt, www.gitverlag.com/go/git.
19. IngleseI, JohnsonRL, SimeonovA, XiaM, ZhengW, AustinCP, AuldDA.High-throughput screening assays for the identification of chemical probes.” Nat Chem Biol. 2007; 3(8), 466–479.
20. Traulau-StewartCJ, WyattCA, KleynDE, AlexA. “Drug discovery: new models for industry-academic partnerships.” Drug Discov Today. 2009; 14 (1/2), 95–101.
21. TyersM, MannM. “From genomics to proteomics.” Nature. 2003; 422, 193–197.
22. SimonCG, Lin-GibsonS.Combinatorial high throughput screening of biomaterials.” Adv Mater. 2011; 23(3), 369–387.
23. YlliperttulaM, Chung, BG, NavaladiA, ManbachiA, UrttiA. “High-throughput screening of cell responses to biomaterials.” Eur J Pharm Sci. 2008; 35, 151–160.
24. DaunertS, BarrettG, FelicianoJS, ShettyR, ShresthS, Smith-SpenceW.Genetically engineered whole cell sensing systems: coupling biological recognition with reporter genes.” Chem Rev. 2000; 100, 2705–2738.
25. WoodKV: “The chemistry of bioluminescent reporter assays.” Promega News. 1998, No.65; p. 14.
26. PerezFA, MuleroV, and CayuelaML: “Application of dual-luciferase reporter assay to the analysis of promoter activity in zebra fish embryos.” BMC Biotec. 2008; 8:81; pp-1–8.
27. Promega Dual Luciferase Reporter System Technical Manual. Revised August 2006: Part No. TM046, Promega Corp. Madison, WI, USA.
28. NakjamaY, KimuraT, SugataK, EnomotoT, AskawaA, IkedaM, OhmiyaY. “Multicolor luciferase assay system: one step monitoring of multiple gene expressions with a single substrate.” BioTechniques. 2005; 38, 891–894.
29. HidaN, AwaisM, TakeuchiM, UenoN, TashiroM, TakagiC, SinghT, HayashiM, OhmiyaY, OzawaT.High-sensitivity real-time imaging of dual protein-protein interactions in living subjects using multicolor luciferases.”PLoS One. 2009; 4(6), e5868.
30. HallisTM, KoppAL, GibsonJ, LebakkenCS, HancockM, Van Den Heuvel-KramerK, Turek-EtienneT. “An improved b-lactamase reporter assay: multiplexing with cytotoxicity readout for enhanced accuracy for hit detection.” J Biomol Screen. 2007; 12(5), 635–644.
31. SteinDC, CarrizosaE, DunhamS. “Use of nfsB, encoding nitroreductase, as a reporter gene to determine the mutational spectrum of spontaneous mutations in Neisseria gonorrhoeae.” BMC Microbiol. 2009; 9, 239.
32. AuldDS, ZhangYQ, VeithH, Jadhav, A, YasgarA, SimeonovA, ZhengW, MartinezED, WestwickJK, AustinCP, IngleseJ. “Fluorescent protein bases cellular assays analyzed by laser scanning microplate cytometry in 1536-well format.” Methods in Enzymo. 2006; 414, 566–589.
33. PrasherDC, EckenrodeVK, WardWW, PrendergastFG, CormierMJ.Primary structure of the Aequorea victoria green-fluorescent protein.” Gene. 1992; 111, 229–233.
34. ChalfieM G, EuskirchenG, WardWW, PrasherDC. “Green fluorescent protein as a marker for gene expression.” Science. 1994; 263, 802–805
35. KremersG-J, GilbertSG, CranfillPJ, DavidsonMW, PistonDW. “Fluorescent proteins at a glance.” J Cell Sci. 2011; 124(2), 157–160.
36. ZanellaF, LorensJB, InkW. “High content screening: seeing is believing.” Trends Biotechnol. 2010; 28(5), 237–245.
37. ShuX, RoynatA, LinMZ, AguileraTA, Lev-RamV, SteibachPA, TsienRY. “Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome.” Science. 2009; 234, 804–807.
38. PistonDW, PattersonGH, Lippincott-SwartzJ, ClaxtonNS, DavidsonMW. “Introduction to fluorescent proteins.” 2010. http://www.microscopyu.com/articles/livecellimaging/fpintro.html.
39. LukyanovKA, ChudakovDM, LukyanovS, and VerkhushaVV.Innovation: photoactivatable fluorescent proteins.” Nat Rev Mol Cell Biol. 2005; 6, 885–891.
40. AlbertsB, JohnsonA, LewisJ, RaffM, RobertsK, WalterP. Molecular Biology of the Cell, 5th edition. New York: Garland Science, Taylor & Francis; 2008.
41. GregoryKJ, SextonPM, ChristopoulosA. HickCA. 2010 second messenger assays for G protein-coupled receptors: cAMP, Ca2+, inositol phosphates, ERK1/2. In G Protein-Coupled Receptors: Essential Methods, edited by D.R. Poyner, M. Wheatley. Oxford, UK: Wiley-Blackwell.
42. SchroederKS, NeagleBD. “FLIPR: a new instrument for accurate, high throughout optical screening.” J Biomol Screen. 1996; 1(2), 75–80.
43. WhitakerKL, SullivanJP, GopalakrishnanM. “ Cell-based assays using Fluorometric Imaging Plate Reader (FLIPR).” Curr Protoc Pharmacol 2000; 9.2.1–9.2.23.
44. Summary of molecular probes fluorescent Ca2+ indicators. In The Molecular Probes® Handbook, 11th edition. 2011. Life Technologies, Grand Island, NY.
45.“FLIPR Assays to measure GPCR and ION Channel Targets” 2011. http://www.ncgc.nih.gov/guidance/section9.html.
46. TitusSA, BeachamD, ShahaneSA, SouthallN, XiaM, HuangR, HootenE, ZhaoY, ShouL, AustinCP, ZhengW. “A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.” Anal Biochem. 2009; 394(1), 30–38.
47. GollaR, SeethalaR. “A homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists.” J Biomol Screen. 2002; 7(6), 515–525.
48. ClaverieJM, NotredameC. Bioinformatics for Dummies. Wiley; Hoboken, NJ, 2003.
49. BaxevanisAD, OuelletteBFF. (eds.) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, third edition. Wiley, 2005. ISBN 0–471-47878–4.
50. CongreveM, MurrayCW, BlundellTM. “Structural biology and drug discovery.” Drug Discov Today. 2005; 10(13), 895–907.
51. DingS, SchultzPG. “A role for chemistry in stem cell biology.” Nat Biotech. 2004; 22(7), 833–840.
52. KorblingM, PrzepiorkaD, HuhYO, EngelH, van BesienK, GiraltS, AnderssonB, KleineHD, SeongD, DeisserothAB. “Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.” Blood. 1995; 85(6), 1659–1665.
53. TakahashiK, TanabeK, OhnukiM, Narita M, IchisakaT, TomodaK, YamanakaS. “Induction of pluripotent stem cells from adult human fibroblasts by defined factors.” Cell. 2007; 131(5), 861–872.
54. SoldnerF, HockemeyerD, BeardC, GaoQ, BellGW, CookEG, HargusG, BlakA, CooperO, MitalipovaM, IsacsonO, HJaenischR.Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.” Cell 2009; 136(5), 964–977.
55. Kim, S-K. “Converting human skin cells to neurons: a new tool to study and treat brain disorders?Cell Stem Cell. 2011; 9, 179–180.
56. IedaM, FuJ-D, Delgado-OlguinP, VedanthamV, HyashiY, BruneauB, SrivastavaD. “Direct reprogramming if fibroblasts into functional cardiomyocytes by defined factors.” Cell. 2010; 142, 375–386.
57. ChristGJ, ChenAF.The grand challenge for integrative and regenerative pharmacology.” Front Pharmacol. 2011; 2 (5), 1–2.
58. ChristGJ, FurthME.Regenerative pharmacology for diabetes mellitus.” Mol Interven. 2009; 9(4), 171–174.
59. MozettaC, MinettiG, PuriPL. “Regenerative pharmacology in the treatment of genetic disorders: the paradigm for muscular dystrophy.” Int J Biochem Cell Biol. 2009; 41, 701–710.
60. BegleyS, CarmichaelM. “Desperately seeking cures: how the road from promising scientific breakthrough to real-world remedy has become all but a dead end.” Newsweek. 2010; May 31, pp. 38–42.
61. BorelJF. “History of the discovery of cyclosporine and of its early pharmacological development.” Wien Klin Wochenschr. 2002; 114(12), 433–437.
62. LeeJA, UhlickMT, MoxhamCM, TomandlD, SallDJ. “Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.” J Med Chem. 2012; 55, 4527–4538.
63. IngleseJ, ShamuCE, GuyRK.Reporting data from high-throughput screening of small-molecule libraries.” Nat Chem Biol. 2007; 8(3), 438–441.